Matinas Biopharma Holdings, Inc. (NYSE:MTNB) Short Interest Down 59.7% in October

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 32,400 shares, a decline of 59.7% from the October 15th total of 80,400 shares. Currently, 0.7% of the shares of the company are short sold. Based on an average trading volume of 188,500 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MTNB. Alliance Global Partners lowered Matinas Biopharma from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Maxim Group reissued a “hold” rating on shares of Matinas Biopharma in a research report on Thursday, October 31st.

Matinas Biopharma Price Performance

NYSE MTNB traded down $0.04 during trading on Wednesday, reaching $0.71. The company’s stock had a trading volume of 173,094 shares, compared to its average volume of 75,777. Matinas Biopharma has a 12 month low of $0.50 and a 12 month high of $21.50.

Matinas Biopharma (NYSE:MTNB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02).

Institutional Trading of Matinas Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Towercrest Capital Management acquired a new stake in Matinas Biopharma in the second quarter valued at approximately $299,000. Alliance Wealth Management Group acquired a new position in Matinas Biopharma in the second quarter worth about $299,000. Finally, Highbridge Capital Management LLC acquired a new position in shares of Matinas Biopharma during the second quarter valued at $1,685,000. 11.77% of the stock is currently owned by institutional investors.

Matinas Biopharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.